These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 2189014

  • 1. Tiazofurin: biological effects and clinical uses.
    Tricot G, Jayaram HN, Weber G, Hoffman R.
    Int J Cell Cloning; 1990 May; 8(3):161-70. PubMed ID: 2189014
    [Abstract] [Full Text] [Related]

  • 2. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot GJ, Jayaram HN, Lapis E, Natsumeda Y, Nichols CR, Kneebone P, Heerema N, Weber G, Hoffman R.
    Cancer Res; 1989 Jul 01; 49(13):3696-701. PubMed ID: 2567208
    [Abstract] [Full Text] [Related]

  • 3. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot G, Weber G.
    Anticancer Res; 1996 Jul 01; 16(6A):3341-7. PubMed ID: 9042309
    [Abstract] [Full Text] [Related]

  • 4. Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis.
    Wright DG, Boosalis MS, Waraska K, Oshry LJ, Weintraub LR, Vosburgh E.
    Anticancer Res; 1996 Jul 01; 16(6A):3349-51. PubMed ID: 9042310
    [Abstract] [Full Text] [Related]

  • 5. Tiazofurin: molecular and clinical action.
    Weber G, Prajda N, Abonyi M, Look KY, Tricot G.
    Anticancer Res; 1996 Jul 01; 16(6A):3313-22. PubMed ID: 9042306
    [Abstract] [Full Text] [Related]

  • 6. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies.
    Malek K, Boosalis MS, Waraska K, Mitchell BS, Wright DG.
    Leuk Res; 2004 Nov 01; 28(11):1125-36. PubMed ID: 15380335
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Hematological and biochemical action of tiazofurin (NSC 286193) in a case of refractory acute myeloid leukemia.
    Tricot GJ, Jayaram HN, Nichols CR, Pennington K, Lapis E, Weber G, Hoffman R.
    Cancer Res; 1987 Sep 15; 47(18):4988-91. PubMed ID: 3476200
    [Abstract] [Full Text] [Related]

  • 9. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
    Wright DG, Boosalis M, Malek K, Waraska K.
    Leuk Res; 2004 Nov 15; 28(11):1137-43. PubMed ID: 15380336
    [Abstract] [Full Text] [Related]

  • 10. Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells.
    Carney DN, Ahluwalia GS, Jayaram HN, Cooney DA, Johns DG.
    J Clin Invest; 1985 Jan 15; 75(1):175-82. PubMed ID: 2856924
    [Abstract] [Full Text] [Related]

  • 11. Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis.
    Jayaram HN, Cooney DA, Grusch M, Krupitza G.
    Curr Med Chem; 1999 Jul 15; 6(7):561-74. PubMed ID: 10390601
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sequential impact of tiazofurin and ribavirin on the enzymic program of the bone marrow.
    Prajda N, Hata Y, Abonyi M, Singhal RL, Weber G.
    Cancer Res; 1993 Dec 15; 53(24):5982-6. PubMed ID: 7903199
    [Abstract] [Full Text] [Related]

  • 14. Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient.
    Weber G, Nagai M, Natsumeda Y, Eble JN, Jayaram HN, Paulik E, Zhen WN, Hoffman R, Tricot G.
    Cancer Commun; 1991 Mar 15; 3(3):61-6. PubMed ID: 1705812
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In vitro and in vivo antiproliferative activity of IPCAR, a new pyrazole nucleoside analog.
    Pani A, Marongiu ME, Pinna E, Scintu F, Perra G, Montis AD, Manfredini S, La Colla P.
    Anticancer Res; 1998 Mar 15; 18(4A):2623-30. PubMed ID: 9703919
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Phase II trial of tiazofurin in recurrent squamous cell carcinoma of the head and neck.
    Dimery IW, Neidhart JA, McCarthy K, Krakoff IH, Hong WK.
    Cancer Treat Rep; 1987 Apr 15; 71(4):425-6. PubMed ID: 3548960
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.